The inner ear contains the sensory organs for hearing and balance. Both hearing and balance are commonly affected in individuals with CHARGE syndrome (CS), an autosomal dominant condition caused by heterozygous pathogenic variants in the CHD7 gene. Semicircular canal dysplasia or aplasia is the single most prevalent feature in individuals with CHARGE leading to deficient gross motor skills and ambulation.
The inner ear contains the sensory organs for hearing and balance. Both hearing and balance are commonly affected in individuals with CHARGE syndrome (CS), an autosomal dominant condition caused by heterozygous pathogenic variants in the CHD7 gene. Semicircular canal dysplasia or aplasia is the single most prevalent feature in individuals with CHARGE leading to deficient gross motor skills and ambulation.
Identification of CHD7 as the major gene affected in CHARGE has enabled acceleration of research in this field. Great progress has been made in understanding the role of CHD7 in the development and function of the inner ear, as well as in related organs such as the middle ear and auditory and vestibular neural pathways. The goals of current research on CHD7 and CS are to (a) improve our understanding of the pathology caused by CHD7 pathogenic variants and (b) to provide better tools for prognosis and treatment. Current studies utilize cells and whole animals, from flies to mammals. The mouse is an excellent model for exploring mechanisms of Chd7 function in the ear, given the evolutionary conservation of ear structure, function, Chd7 expression, and similarity of mutant phenotypes between mice and humans. Newly recognized developmental functions for mouse Chd7 are shedding light on how abnormalities in CHD7 might lead to CS symptoms in humans. Here we review known human inner ear phenotypes associated with CHD7 pathogenic variants and CS, summarize progress toward diagnosis and treatment of inner ear-related pathologies, and explore new avenues for treatment based on basic science discoveries.
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| CLINICAL EVALUATION AND MANAGEMENT OF HEARING IN CS
Hearing loss is one of the most commonly recognized phenotypic features seen in CHARGE Syndrome (CS). The clinical evaluation and management of ear, hearing, and vestibular issues is critical for optimizing the potential for communicative development and function of these patients, and the degree of hearing loss is correlated with delays in receptive and expressive language development (Vesseur, aerodigestive conditions) that delay other tests and interventions.
Underlying this complex clinical scenario is the imperative of providing optimal access to sound and speech during a critical developmental window (birth to 3-years of age) when the developing brain is most amenable to learning speech and language. Taken together, the management of auditory and vestibular issues in CS is extremely challenging and complex.
In most instances, identification of hearing loss in cases of suspected or known CS occurs early in the newborn period. The vast majority of infants with CS are now identified in the neonatal period, and birthing facilities are now associated with higher acuity newborn intensive care units where universal newborn hearing screening is included in standard protocols of postnatal care. As a result, congenital hearing losses in cases of CS are typically identified very early in the clinical course. Importantly, children born far from tertiary medical centers or those who lack access to comprehensive medical care should still be considered at risk for complications from delays in diagnosis and intervention.
The hearing loss in CS can be sensorineural (SNHL) due to anomalies of the cochlea, cochlear nerve or other inner ear structures (e.g., vestibular aqueduct) (Figures 1-5 ). The hearing loss also can be purely conductive (CHL) due to malformations of the external and middle ear structures ( Figure 6 ). Very commonly, the hearing loss in CS is mixed due to a combination of inner, middle, and external ear phenotypes. Initial hearing screening methodologies in newborn intensive care settings typically employ an Auditory Brainstem Response (ABR) technique that detects hearing loss. However, when patients fail the screening newborn ABR test, best practice entails performance of a newborn hearing loss diagnostic battery that includes a more rigorous, frequencyspecific ABR protocol, including otoacoustic emission testing to probe cochlear hair cell function, and immittance testing that assesses the health of the middle ear (e.g., tympanometry, etc.). Attempts are made to perform these tests in natural sleep conditions, but given the frequent anesthetics that infants with CS undergo, they may also be performed in conjunction with other procedures under anesthesia (imaging studies, cardiac testing, endoscopies, etc.) (Edwards, Kileny, & Van Riper, 2002; Edwards, Van Riper, & Kileny, 1995) .
| COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING
Once the type (SNHL, CHL, mixed hearing loss) and severity of the hearing loss are established, diagnostic work-up is coordinated with a plethora of other tests and procedures that are commonly performed for individuals with CS. Best practices in CS typically include obtaining both Computed Tomography (CT) and Magnetic Resonance (MR) imaging of the inner ear and brain in order to adequately visualize the bony structural pathology and the soft tissue/neural pathologies, respectively.
CT imaging allows examination of the external auditory canal and middle ear ossicular abnormalities and is very sensitive and specific for detecting inner ear pathology. Malformations of the cochlea and vestibular system are well-demonstrated on CT, as are anomalies of the internal auditory canal. Anomalies of these structures are very common findings in the context of CS (Figures 1-5 ). CT imaging, however, has certain limitations that are particularly relevant in CS. For example, while the conduit for the cochlear nerve is demonstrable by CT imaging, the actual nerve is not. The cochlear nerve can be deficient or absent in CS, and the identification of cochlear nerve deficiency has great relevance in hearing intervention strategies. Finally, it should be remembered that CT involves exposure to ionizing radiation, and while most tertiary centers now employ protocols that minimize this radiation exposure (i.e., microdose CT), many individuals with CS require an extraordinary number of X-rays and scans that could result in a potentially unsafe cumulative exposure to radiation.
MR imaging offers extraordinary ability in demonstrating soft tissue structures and brain anomalies that are commonly seen in CS, and is an essential diagnostic tool for evaluating the inner ear for hearing (and balance) problems. Parasagittal MR images are the gold standard and offer the highest sensitivity for assessing the VIIIth cranial nerve by imaging. In contrast to CT, where only the channel for the cochlear nerve is visible, MR imaging demonstrates the nerve itself but does not permit detailed assessment of the bony conduit (Figure 4) . MR is also useful in delineating cochlear hypoplasias and other malformations via demonstration of fluid in the scalae of the cochlea. MR also offers the great advantage of avoiding any exposure to ionizing radiation for these patients. Aural rehabilitation in these cases is discussed in more detail below.
| HEARING AIDS AND AUDITORY IMPLANTS IN CS
Characterization of hearing loss informs aural rehabilitative strategies, which should be instituted as soon as possible in order to optimize audiologic outcomes. In practice, however, aural rehabilitation may be delayed due to priorities of management of life-threatening medical conditions and the frequent need for prolonged hospitalizations early in life (Blake et al., 1998) . Options for hearing amplification include conventional hearing aids, bone-anchored hearing aids (BAHAs), cochlear implantation (CI), and auditory brainstem implantation (ABI). Selection of an appropriate rehabilitative modality is best achieved with a In general, conventional hearing aids may be appropriate for children with patent external auditory canals and serviceable hearing.
In children with CS, however, the presence of external ear anomalies (e.g., microtia) may complicate hearing aid mold fitting. Similarly, recurrent or chronic otitis media and otorrhea are common and may limit safe use of an occlusive hearing aid mold. Episodic or progressive middle ear disease may result in changes in the severity of CHL and degree of benefit from conventional hearing aids.
In individuals with CS, the presence of CHL may often be attributable to abnormalities of the middle ear. Middle ear abnormalities in CS occur in a spectrum of severities and may affect multiple components of the bony architecture of the middle ear cleft. Occurring in up to 80% of CS ears (Ha, Ong, Wood, & Vijayasekaran, 2016) , ossicular anomalies range from dysplasia to absence of the malleus, incus or stapes. Ossicular fixation may also occur, with fixation of the head of the malleus to the anterior tympanic wall being the most frequent event (Dhooge et al., 1998) . Dysplasia or aplasia of the round window or oval window are also possible. Patients with conductive hearing loss, regardless of the anatomic correlate accounting for the hearing deficit, may be candidates for BAHA devices, which transmit sound to the cochlea via bone conduction. Many cases of CHL may also be treated by alternative surgical means. Ossicular chain abnormalities such as fixation or dysplasia/absence are also amenable to targeted surgical approaches, which vary depending on the specific ossicular abnormality. The goal of such an operation is to establish a mobile, continuous conductive mechanism that effectively transmits a sound wave to a functional cochlea. In certain anatomic circumstances, such as absence or dysplasia of one or more ossicles, placement of an ossicular reconstruction prosthesis may be indicated to restore coupling of the tympanic membrane to the oval window of the cochlea, resulting in significant hearing improvement. Surgical correction of conductive hearing loss is not indicated in the setting of nonserviceable hearing or medical unfitness for general anesthesia.
For children with severe to profound SNHL, CI may provide dramatically improved access to sound and speech that could not be obtained by other, more conservative, interventions. CI surgery traditionally entails performance of a mastoidectomy and facial recess approach, followed by insertion of an electrode array into the cochlear lumen. The receiver-stimulator component of the implant is situated atop the temporoparietal skull, deep to the soft tissues. After implantation, the patient applies an external speech processor to the skin overlying the receiver-stimulator. The speech processor transforms and transmits the sound information to the receiverstimulator. In turn, the receiver-stimulator transmits the electronic signal to the electrode array, which stimulates the spiral ganglion neural elements within the cochlear modiolus.
Candidacy for CI is best determined in multidisciplinary evaluation by Audiology and Otolaryngology consultants and is typically reserved for children who have gained little or no hearing benefit with conventional hearing amplification. Although the potential for significant hearing FIGURE 4 (a) A parasagittal oblique T2-weight fast-spin echo MR image demonstrates an internal auditory canal of normal caliber. The arrow points to an intact cochlear nerve, which runs anteroinferiorly within the canal. (b) In this individual with CS, the cochlear nerve is not readily distinguishable in its expected location (arrow). This is an example of cochlear nerve deficiency, a collective term used to describe hypoplasia and aplasia of the nerve (Song et al., 2011) . In turn, the authors recommend that CI be considered in individuals with CHARGE when the diameter of the cochleovestibular nerve is larger than or equal to the diameter of the facial nerve on MRI and cognitive developmental delay is not severe. reviewed ten children with CS who underwent CI and found that all children displayed auditory benefit and improved disease-specific quality-of-life. On comparing these children to a cohort of patients with CS and sufficient hearing without CI, the authors found that children implanted at a young age (37 months or younger) with a long period of CI use (>5 years) and minor comorbidities developed spoken language at a level comparable to children with CS and no CI. In children who are deemed to be candidates for CI, implantation should be performed early to maximize the potential for auditory benefit.
It should be noted that although multiple CI device models are now MRI-compatible, many are not FDA-approved for MRI compatibility.
When considering a child's candidacy for CI, the surgeon, CI team, and family must account for the potential need for repeated imaging tests. As occurs with any metal-containing device, the receiver-stimulator portion of the CI produces a shadow on CT imaging. The magnet component of the CI also produces a shadow on MR imaging. These shadow artifacts may be problematic for patients who require serial neuroimaging to monitor progression of lesions/masses. In these cases, implantation of the ear contralateral to the lesion and/or MRI-compatible CI may be advisable, depending on each patient's anticipated imaging protocol.
CI surgery may be technically challenging in children with CS due to the abnormal temporal bone anatomy. Structures that normally serve as important anatomic landmarks during temporal bone surgery may be dysplastic or completely absent in the context of CS. In conventional CI surgery, mastoidectomy facilitates visualization of, and access to the middle ear, and basal turn of the cochlea. Once the middle ear is accessed, the tympanic segment of the facial nerve, oval window, stapes, cochlear promontory, and round window typically orient the surgeon to the expected location of the scala tympani within the basal turn of the cochlea. performed a review of temporal bone CT findings in patients with CS and cataloged the potential impact of these findings with respect to CI surgery. As the authors describe, the presence of an underdeveloped mastoid in CS may impede access to the middle ear.
Similarly, the horizontal semicircular canal, an important landmark located at the medial wall of the antrum, normally indicates the approximate depth of the mastoid segment, and second genu of the facial nerve within the temporal bone. This structure, however, may be dysplastic or absent in children with CS. In this situation, the surgeon may skeletonize the tegmen mastoideum and follow it medially as it forms the superior boundary of the antrum. According to in the middle ear, the tympanic segment may take an aberrant course over the cochlear promontory (19% of ears) and also the round window (9.5% of ears), potentially impeding insertion of the CI electrode into the cochlea. The oval window and/or round window may also be atretic or otherwise underdeveloped. These anomalies pose a significant challenge when planning placement of the cochleostomy. The facial nerve, if taking an aberrant course over the promontory and round window, may be at risk during formation of the cochleostomy (Ahn & Lee, 2013) and may necessitate abortion of the procedure (Bauer, Goldin, & Lusk, 2002) .
Furthermore, the presence of anomalies of the oval window, round window, and/or ossicular chain may distort the surgeon's sense of the location of the scala tympani at the basal turn of the cochlea . In order to avoid surgical misadventure, it is imperative that the surgeon carefully review preoperative imaging before proceeding with surgery.
In patients with cochlear nerve deficiency who demonstrate no auditory perception or who have received but failed to benefit from CI, ABI may be an option. ABI surgery entails performance of a retrosigmoid craniotomy approach and placement of an implant electrode array next to the cochlear nucleus complex of the lateral brainstem. Similar to CI, a receiver-stimulator component is affixed atop the temporoparietal skull, deep to the soft tissues of the scalp. Historically, ABI has been reserved otolith function, vertical, and horizontal translational movement may be incorporated into therapy to aid in organization of balance. As described in multiple reports (Abadie et al., 2000; Murofushi et al., 1997) , children with congenitally absent vestibular function can achieve motor milestones, presumably by compensatory use of visual and/or proprioceptive input. In line with these reports, vestibular rehabilitation therapy remains a primary treatment option for many patients with CS and offers a remarkably effective and safe intervention. Although the impact of vestibular dysfunction on global intellectual development in CS is poorly studied, one report by Raqbi et al. (2003) suggests that the presence semicircular agenesis or vestibular and otolithic deficiency does not portend poor cognitive function. As our understanding of inner ear vestibular anomalies improves (as well as the functional implications of those anomalies), so will the potential to enhance and develop novel interventions for those vestibular dysfunctions.
| CHD7 GENE STRUCTURE, EXPRESSION, EVOLUTIONARY CONSERVATION, AND FUNCTION
CHD7 is the gene most commonly affected in CS. CHD7 encodes an ATPdependent chromatin remodeling protein and member of the chromodomain helicase DNA binding protein family (Vissers et al., 2004) . In humans, CHD7 is located on chromosome 8q12 and encompasses 188 kb of DNA. Human CHD7 contains 38 exons, 37 of which are coding. There is a high degree of homology between CHD7 in humans and other organisms, including mouse, zebrafish, fly, and yeast. In mouse, Chd7 is expressed in the oocyte (Cheng et al., 2013) , in embryonic stem cells (Schnetz et al., 2009) , and is broadly expressed in the e7.5 embryo (Randall et al., 2009) , after which time it is gradually down-regulated during embryogenesis (Bosman et al., 2005; Hurd et al., 2007) . Eventually, Chd7 expression becomes enriched in specific cells and tissues, especially in organs where malformations are known to occur in CHARGE. CHD7 is localized primarily to the nucleus, although a recent study suggested it may also localize to inner ear stereocilia (Bird et al., 2017) . Chd7 expression in mouse neural tissues likely reflects its important functions in a wide variety of peripheral and central nervous system regions. In the mouse ear, Chd7 is highly expressed in the e9.5 otocyst and surrounding mesenchyme, and over the next 8 days of gestation becomes concentrated in VIIIth nerve ganglion neurons and in auditory and vestibular sensory epithelia (Hurd, Poucher, Cheng, Raphael, & Martin, 2010) .
Like other ATP-dependent chromatin remodeling proteins, CHD7 uses the energy of ATP to slide nucleosomes along DNA or evict them (Bouazoune & Kingston, 2012) . CHD7 binds to linker DNA adjacent to nucleosomes (Manning & Yusufzai, 2017) . CHD7 is enriched at sites of methylated histone H3 residues at promoters and enhancers (Elkareh et al., 2009 ). CHD7 has been identified at over 10,000 regions of the genome in both mouse and human (Schnetz et al., 2010) . CHD7
participates in large multi-protein complexes (Bajpai et al., 2010) 
| CHD7 MUTANT MOUSE MODELS AND PHENOTYPES
The first report of Chd7 mutations in the mouse came from the description of a series of nine different Chd7 alleles (Edy, Todo, Whi, Lda, Obt, Cycn, Mt, Dz, Flo) and another allele (Whl) that mapped to the same region of mouse chromosome 4 (Bosman et al., 2005) . Most of these alleles had been generated using Ethyl-Nitrosourea (ENU) in a screen for mutations that result in hyperactivity and circling behaviors (Alavizadeh et al., 2001; Hawker, Fuchs, Angelis, & Steel, 2005; Kiernan et al., 2002; Nolan et al., 1995; Pau, Hawker, Fuchs, De Angelis, & Steel, 2004; Pickard, Sollars, Rinchik, Nolan, & Bucan, 1995) .
Each of these mutant mice harbors a heterozygous loss of function variant in the Chd7 gene, and exhibits phenotypes including hyperactivity, head-bobbing, circling, and structural abnormalities of the semicircular canals. In addition to the inner ear phenotypes, choanal atresia, clefting, cardiac malformations, genital hypoplasia, reduced growth, and embryonic lethality at mid-gestation were also reported, strengthening the argument that these mice are an excellent model for human CS (Bosman et al., 2005) .
In subsequent studies, the Martin laboratory generated a Chd7 gene trapped allele (Chd7 Gt ) that proved useful for tracking Chd7 expression in mouse cells and tissues . Analysis of
Chd7
Gt/+ mice uncovered additional new phenotypes including mixed conductive and sensorineural hearing loss, middle ear structural abnormalities, and defects in highly specific regions of the vestibular system including lack of innervation to the posterior crista ampullaris Hurd et al., 2007 Hurd et al., , 2011 .
To overcome the embryonic lethality caused by complete loss of Chd7, three groups have generated and studied Chd7 conditional deletion mice (Feng et al., 2013; Hurd et al., 2010; Jones et al., 2015) .
Another group created an allele that allows for recovery of Chd7 deletion (Randall et al., 2009 ). Use of these mice has allowed for the discovery of new roles for Chd7 in inner ear development, including abnormalities of the sensory epithelia in the vestibular system. A series of studies led to the novel observation that CHD7 plays a critical role in neurogenesis of the inner ear as early as e9.5 (Hurd et al., 2010) . This requirement of CHD7 for proper neuronal development was also been observed in the nasal epithelium and in gonadotropin releasing hormone-expressing neurons, and may help explain the abnormal olfaction and lack of pubertal development observed in individuals with CHARGE (Layman et al., 2009; Layman, Hurd, & Martin, 2011) .
| PLEIOTROPIC ROLES FOR CHDIN NEUROGENESIS OF THE INNER EAR AND OTHER AREAS OF THE NERVOUS SYSTEM
In addition to the inner ear, CHD7 has been implicated in neurogenesis of the forebrain subventricular zone, where newly born neurons migrate rostrally to populate the olfactory bulb (Micucci et al., 2014) .
Loss or reduction of this progenitor population might explain why arhinencephaly (reduced size or absence of the olfactory bulbs) is a common MRI finding in CHARGE (Legendre et al., 2012) . Interestingly, Chd7 was recently shown to regulate granule cells in the cerebellum and stem cells in the hippocampus, raising the possibility that auditory and vestibular neural pathways in the brain may also be sensitive to Chd7 loss (Feng et al., 2013 (Feng et al., , 2017 Jones et al., 2015; Whittaker et al., 2017) . Use of heterozygous mutant Chd7 mice has also led to the discovery that haploinsufficiency for Chd7 may protect from noiseinduced hearing loss, likely related to conductive hearing loss and middle ear structural abnormalities (Hurd et al., 2011) .
Identification of the specific cells that express Chd7 and/or the cells that are affected by Chd7 loss is crucial for developing therapies.
Studies of the inner ears of wild type mice have localized Chd7 to the sensory organs and the neural elements of both cochlear and vestibular portions of the inner ear during development (Hurd et al., 2010 (Hurd et al., , 2011 . In sensory organs, Chd7 is expressed in both epithelial and mesenchymal derivatives (Hurd et al., 2010) . In mature ears, Chd7 expression appears to be concentrated in sensory epithelia and in neurons, suggesting that therapies targeting these cells for therapeutic approaches may be the most efficacious.
Despite the rapid progress and new knowledge acquired about Gjb2 (Maeda, Fukushima, Nishizaki, & Smith, 2005) . They injected Gjb2 siRNA into the cochlea and induced downregulation of Gjb2 expression, which partially improved hearing in these mice. Their study showed the utility of using siRNA for treating genetic deafness, and demonstrated that the function of the protein was not altered by manipulation of its level in tissues. Importantly, however, the direct relevance of this work to CS may be limited because the majority of CHD7 pathogenic variants in humans involve reduction of protein levels.
Among hereditary forms of human hearing loss, autosomal recessive pathogenic variants in GJB2, the gene encoding Connexin 26, are the most common. The high incidence of these variants in the population has inspired studies on phenotypic rescue in Gjb2 mutant mice. Two recent studies used mice with conditional deletions of Gjb2, one expressing panotic Foxg1-Cre (Foxg1-cCx26KO) (Yu et al., 2014) , and the other expressing Cre recombinase under the control of the supporting cellspecific P0 promoter (Cx26fl/fl;P0-Cre) (Iizuka et al., 2015) . Both studies rescue inner ear structure and improve hearing (Chang et al., 2015) .
The laboratories of Geleoc and Holt (Pan et al., 2017) Many individuals with CS have heterozygous nonsense pathogenic variants of Chd7 that could be amenable to therapies to induce ribosomal read-through (Brendel, Klahold, Gartner, & Huppke, 2009 ).
Aminoglycosides and other drugs can enable ribosomes to bypass premature termination codons and allow translation to proceed, albeit with insertion of alternative amino acids. Preliminary experiments have provided proof-of-principle for this approach, but the efficiency at present remains low (∼1-5%) (Vecsler et al., 2011) . Future improvements of these drugs could enhance their efficiency; however, aminoglycosides are ototoxic, and special care will be needed to avoid negative outcomes in the inner ear.
Animal models show that some viral vectors transduce hair cells with high efficiency when injected into the cochlear fluids (Askew et al., 2015; Yu et al., 2014) , whereas others, especially adenovirus, are very poor at transducing mature hair cells (Kawamoto, Ishimoto, Minoda, Brough, & Raphael, 2003; Venail et al., 2007) . In some cases, injections into scala media can enhance transduction of supporting cells (Ishimoto, Kawamoto, Kanzaki, & Raphael, 2002 ) but these may not be the optimal targets for treating CS. It should also be considered that in the human inner ear, access to the scala media is not available with current surgical technology.
A final consideration for gene therapy is that any injection of reagents into the inner ear may have significant side effects that need to be considered and compared to potential benefits. Among the many 
